Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc. (CTMX)
:CTMX
Cx-2051
Solid Tumor, Adult
Phase I
Recruiting
First In Human Study of CX-2051 in Advanced Solid Tumors
Feb 12, 2024
―
Cx-904
Solid Tumors
Phase I
Terminated
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
May 19, 2022
―
Ipilimumab, Vemurafenib, Cx-072
Lymphoma, Solid Tumor
Phase I/II
Terminated
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Dec 26, 2016
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does CytomX Therapeutics Inc. (CTMX) have in its pipeline
CTMX is currently developing the following drugs: Cx-2051, Cx-904, Ipilimumab, Vemurafenib, Cx-072. These drug candidates are in various stages of clinical development as the company works toward FDA approval.